Healthcare

Soleno Therapeutics to Participate in Upcoming November Conferences

REDWOOD CITY, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel…

2 months ago

Cidara Therapeutics to Participate in November Investor Conferences

SAN DIEGO, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak®…

2 months ago

Josh Ruben Joins PetVivo Holdings, Inc. Board of Directors

MINNEAPOLIS, MN, US, Oct. 28, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX: PETV; OTCID PETVW), in cooperation with its…

2 months ago

Targeted Genomics Launches CeliacDx Consumer-Initiated Testing Service

IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Targeted Genomics LLC, developer of GlutenID, the only U.S. Food and Drug…

2 months ago

AssistRx Named a Winner of the Orlando Sentinel Media Group’s Central Florida Top Workplaces 2025 Award

Healthcare technology and patient solutions provider recognized as a Central Florida top employer for fifth consecutive yearORLANDO, Fla., Oct. 28,…

2 months ago

R1 Welcomes Estelle Barnes to Lead Enterprise Customer Engagement and Partnerships

MURRAY, Utah, Oct. 28, 2025 (GLOBE NEWSWIRE) -- R1 (“R1” or the “Company”), the leader in healthcare revenue management, today…

2 months ago

Kestra Medical Technologies to Present at the Stifel 2025 Healthcare Conference

KIRKLAND, Wash., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital…

2 months ago

Madrigal to Present New Data from the Company’s MASH Program at AASLD’s The Liver Meeting 2025

Two oral presentations to highlight biomarker, imaging and quality-of-life data from the open-label compensated MASH cirrhosis (F4c) arm of the…

2 months ago

ProPhase Labs Engages RedChip Companies to Lead Investor Relations Efforts

UNIONDALE, NY, Oct. 28, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (the “Company” or “ProPhase”), a next generation…

2 months ago

Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution

– ARCALYST® (rilonacept) Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth –– ARCALYST 2025 expected net…

2 months ago